ProKidney has developed a cell-based product called REACT (Renal Autologous Cell Therapy), designed to build renal function in patients with chronically diseased kidneys. REACT is being developed to delay or prevent renal replacement therapy (dialysis or kidney transplant). ProKidney’s REACT is a percutaneous minimally invasive injectable product composed of the patient’s own regenerative renal cells (RRC).  Because REACT is a personalized medicine composed of a patient’s own cells, there is no need for immunosuppressive therapy used for a patient’s lifetime for kidney transplant.

In the United States, over 500,000 patients per year suffer from diabetic kidney disease.  ProKidney is currently conducting multiple Phase 2 clinical trials for its REACT product. The ProKidney Phase 2 clinical trials are based on a successful internationally conducted Phase 1 clinical trial of the REACT product. Some of the first patients to be injected have been followed for over three years and remain dialysis-free. The trial demonstrated that REACT was well tolerated by patients with moderate to severe diabetic kidney disease.

If you have questions regarding ProKidney or the REACT trial more information is available at, or directly from ProKidney